ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed to improve cytotoxicity against multiple myeloma. Targeting of two tumor-associated an...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Carretero-Iglesia, L, Hall, OJ, Berret, J, Pais, D, Estoppey, C, Chimen, M, Monney, T, Loyau, J, Dreyfus, C, Macoin, J, Perez, C, Menon, V, Gruber, I, Laurendon, A, Caro, LN, Gudi, GS, Matsuura, T, van der Graaf, PH, Blein, S, Mbow, ML, Croasdale-Wood, R, Srivastava, A, Dyson, MR, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR
Médium:	Journal article
Jazyk:	English
Vydáno:	Nature Research 2024

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Podobné jednotky